Webcast Hybrid PET/MR with PETInsert Si198 and Si103

Hybrid PET/MR Enables Exploration of New Science Areas

 · Canada/Eastern

About This Webcast

Preclinical molecular imaging experts Peter Caravan, PhD and Michael Heidenreich, PhD discuss the synergies of PET/MR and the new avenues of research accessible ranging from neuroscience, cancer, and metabolic disease to dual molecular probe development.

Speakers

Dr. Peter Caravan

Dr. Peter Caravan

Institute for Innovation in Imaging (I3) (Co-director) The Caravan Lab (Director) , Harvard University Medical School

Peter Caravan, PhD, is co-director of theInstitute for Innovation in Imaging (I3)at Massachusetts General Hospital and an Associate Professor of Radiology atHarvard Medical School. He leads a multidisciplinary and translationalmolecular imaging lab (the Caravan Lab) focused on the invention of novel molecular probes andtheir broad applications in cardiovascular, pulmonary, renal and hepaticdiseases, as well as in cancers. His research spans novel chemistry technologies from advanced MRI and PET imaging in animal models to applicationsin patient populations. He holds Investigational New Drug (IND)applications for a fibrin-targeted PET tracer and a collagen-targeted PETtracer that are currently being evaluated in 6 clinical trials. He hasinvented molecular probes specific to fibrogenesis, acidosis, inflammationand thrombosis, as well as gadolinium-free MR contrast agents. Dr. Caravan received a PhD in Inorganic Chemistry from the University ofBritish Columbia. Following postdoctoral work at the EPFL (Switzerland), hespent 9 years at Epix Pharmaceuticals developing tissue-specific andresponsive MRI contrast agents, one of which, gadofosveset, was approved by theFDA and the EMA. He co-invented EP-2104R, which was the first molecularlytargeted MRI contrast agent to enter clinical trials. Since joining MGH in2007, he has been continuously funded by the NIH.

Dr. Michael Heidenreich

Dr. Michael Heidenreich

Vice President Nuclear Molecular Imaging , Bruker

Michael received his PhD in C13 MRI imaging from the University of Ulm and joined Bruker in 1999 as an MRI application scientist. In 2005, he was appointed Productline Manager and has been responsible for Brukers BioSpec MRI imaging products for more than 10 years. Since 2016, he is managing the Nuclear Molecular Imaging Business Unit for PET/SPECT/CT and PET/MR imaging solutions with its main R&D and application teams in Valencia/Spain, Kontich/Belgium, Billerica/US and Ettlingen/Germany.